linjc16/ctgov huggingface dataset:
Comparing the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy

Study Overview
=================
Brief Summary
-----------------
The aim of this study was to compare the Antibacterial Efficacy of Diode Laser 810nm and Photodynamic therapy in reducing bacterial microflora in endodontic retreatment of teeth with periradicular lesion.

Detailed Description
-----------------
Conventional techniques of root canal treatments such as mechanical instrumentation and chemical debridement with antimicrobial irrigants, such as Sodium hypochlorite (NaOCl) and chlorhexidine and use of calcium hydroxide do not always suffice to predictably render root canals free of bacteria Using the high-power diode laser is a new approach of disinfection allowing access to the previously unavailable areas, such as the tubular network. This study, therefore, compares two types of diode lasers (low-power and high power) in terms of anti-bacterial effect as well as the conventional endodontic retreatment to determine the ideal method of root canal disinfection.

Official Title
-----------------
Comparing the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy in Reducing the Microbial Flora of the Canal While Root Retreatment in Patients With Periradicular Lesions

Conditions
-----------------
Periradicular Disease

Intervention / Treatment
-----------------
* Device: diode laser
* Device: diode laser
* Drug: Methylene blue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - endodontic retreatment of teeth with periradicular lesion. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 2<br>in the second group diode laser (810 nm, 1.2 W, 30 s) was irradiated. Then second samples were taken from all canals. | Device: diode laser<br>* diode laser<br>|
| Experimental: 1<br>In the first group Photodynamic therapy (PDT) with Methylene blue and diode laser (810 nm, 0.2 W, 40 second) was done | Device: diode laser<br>* MB and diode<br>Drug: Methylene blue<br>* Methylene blue and diode laser was used<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bacterial colony forming unit(CFU/ML) | after doing protocol in each groups CFU /ml for different bacteria will be counted | 12 months |
Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease

Study Overview
=================
Brief Summary
-----------------
This research study will evaluate functions of memory, thinking, behavior, and daily life activities and how these relate to the measurement of certain chemicals (acetylcholine and dopamine) in the brain using an imaging procedure called positron emission tomography (PET). You may know that in Alzheimer's dementia (dementia is a disease where persons become forgetful and confused), a reduction in the amount of acetylcholine, a neurotransmitter substance (a chemical messenger that nerve cells need to communicate with each other), may be responsible for some of the memory and behavioral changes. At the present time, the investigators have no clear information on the levels of acetylcholine in the brain of patients with Parkinson's disease who also have memory or behavioral changes.

Official Title
-----------------
Executive, Activities of Daily Living, and Cholinergic Functions in Parkinson's Disease

Conditions
-----------------
Parkinson's Disease

Intervention / Treatment
-----------------
* Behavioral: Behavioral assessment/questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PDD: Patients who meet the UK Parkinson's Disease Society Brain Bank Research Center (UKPDSBRC) clinical diagnostic criteria for PD with dementia (MMSE 18-25; n=28; age 50-85 years; M/F) are eligible for the study. Hoehn and Yahr stages I-III. PD. Patients with who meet the UKPDSBRC criteria for PD with a MMSE of >25 (n=28; age 50-85 years; M/F). Hoehn and Yahr stages I-III. Normal control subjects (n=16) (age 50-85 years; M/F). No current or past history of neurologic or psychiatric illness. Exclusion Criteria: Any subjects on cholinergic, anti-cholinergic drugs will be excluded from the study. Current or past history of neurologic or psychiatric illness.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Parkinson's disease<br> | Behavioral: Behavioral assessment/questionnaire<br>* Complete behavioral assessment/questionnaire<br>|
| Normal Controls<br> | Behavioral: Behavioral assessment/questionnaire<br>* Complete behavioral assessment/questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Increased Salt Intake in Healthy Men

Study Overview
=================
Brief Summary
-----------------
To study the effects of an increased salt intake on metabolic, cardiovascular and immunoregulatory functions in healthy men.

Official Title
-----------------
Effects of Increased Salt Intake on Metabolic, Cardiovascular and Immunoregulatory Functions in Healthy Men

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: Slow sodium tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: body mass index 18.5 - 29.9 kg/m2 Exclusion Criteria: clinically relevant heart, lung, liver, and kidney diseases

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Slow sodium tablets<br>Increased dietary salt intake | Dietary Supplement: Slow sodium tablets<br>* 6 g sodium chloride per day over 14 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postprandial energy expenditure within 4h after a meal, measured by indirect calorimetry (respiratory chamber) |  | Change to baseline at day 14 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Energy metabolism, Glucose tolerance, Blood pressure, Immunoregulation
Research Study Examining Nerve Block for Migraine

Study Overview
=================
Brief Summary
-----------------
Migraine and the skin sensitivity that accompanies it can go away in minutes after a nerve block, which is a procedure involving an injection of a small amount of a local anesthetic next to a nerve to the skin, causing an area of skin to become numb. We have also noticed that light sensitivity goes away quickly after a nerve block. We would like to see how quickly this happens and how long the benefit of nerve block lasts. We are interested to see if these effects are due to the injection itself or due to the lidocaine. A subject may be asked to participate in this study if a subjects physician has planned for a subject to receive an injection of BOTOX® in the area of the Greater Occipital Nerve (a spinal nerve located at the back of the head) as part of a subjects routine preventive treatment for migraine today.

Official Title
-----------------
Greater Occipital Nerve (GON) Block for Migraine

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Procedure: Greater Occipital Nerve Block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects with episodic or transformed migraine age 18to 80 years old. Subjects must have unilateral migraine headache and trigeminal distribution brush allodynia at the time of injection. Subjects must be able to consent or assent to the study. Exclusion Criteria: Subjects who in their own or in the investigator's opinion are unable to report the severity of four symptoms (pin sharpness to determine efficacy of nerve block, headache severity, photophobia severity and allodynia severity), every 30 seconds for 5 minutes post injection; Subjects with skull defect, or history of injury to the area of the GON. Subjects with prior adverse reaction to GON block, lidocaine or marcaine. Subjects who are pregnant or lactating

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Greater Occipital Nerve Block|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prediction Value of PANX1 in Infection Post Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine prediction value of PANX1 expression in infection post liver transplantation.

Conditions
-----------------
Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients underwent liver transplantation. Exclusion Criteria: re-transplantation multiorgan transplantation living donors or split-liver donors liver transplantation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| liver transplantation grafts<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post-transplant infections | Frequency of clinically or microbiologically documented infection after transplantation. | 90 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PANX1, Infection, Liver transplantation
Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot

Study Overview
=================
Brief Summary
-----------------
Context. Nuclear imaging plays a central role in management of chromaffin-tissue derived tumors because tumor cells exhibit peptide receptors and proteins involved in metabolism that can be targeted with specific radiopharmaceutics. Recently, over expression dopamine-receptor D2 isoforms has been found in endocrine tumors. Objective. The aim of the present study is to evaluate the feasibility of 123I-IBZM (a D2 agonist radiolabelled with 123I) in patients with PHEO and/or PGL. Diagnostic accuracy will be also compared to traditional SPECT imaging procedures.

Conditions
-----------------
Chromaffin-tissue Derived Tumors

Intervention / Treatment
-----------------
* Other: Scintigraphy in 123I-IBZM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age + 18 years. The women in ages to procreate have to have an effective contraception or a negative pregnancy test (in the absence of effective contraception) Having a radiological and functional imaging (balance sheet(assessment) pré--IBZM) considered adapted and complete for the pathology. Having a phéochromocytome or a paragangliome proving a surgical operation in view of the data of the balance sheet(assessment) pré--IBZM. With or without allergy in the iodine. Exclusion Criteria: NEM2A or 2B. Malignant Forms which do not recover from an even partial, surgical gesture(movement). Pregnant Women or in the course of feeding. Women in age to procreate without effective contraception, with positive pregnancy test. Renal insufficiency

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Scintigraphy in 123I-IBZM|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The aim of the present study is to evaluate the feasibility of 123I-IBZM (a D2 agonist radiolabelled with 123I) in patients with PHEO and/or PGL. Diagnostic accuracy will be also compared to traditional SPECT imaging procedures. |  | 3 years |
The Efficacy of Group Therapy in Ultra-Orthodox Jewish Young Men Diagnosed With Type One Diabetes

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the influence of an intervention program especially designed to young ultra orthodox men that were diagnosed with diabetes type one.

Conditions
-----------------
Behavioral Changes

Intervention / Treatment
-----------------
* Behavioral: Lifestyle counseling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Young Ultra-Orthodox men diagnosed with diabetes type one. Exclusion Criteria: Psychiatric illness .

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lifestyle counseling<br> | Behavioral: Lifestyle counseling<br>* group therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the efficacy will be evaluated using Diabetes Quality of Life questionnaire before and after the program. |  | three months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the efficacy will be evaluated using behavioral changes related to diabetes questionnaire before and after the program. |  | three months |
NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the efficacy and tolerance of 2 dosages (750 versus 500 units) of the Dysport type A botulinic toxin for patient suffering from neurogenic urinary incontinence by an overactive bladder and the failure of anticholinergic drugs.

Official Title
-----------------
Evaluation of the Efficacy and Tolerance of 2 Dosages of Type A Botulinic Toxin in Neurogenic Areactive Bladder Resistant to Oral Medical Treatment

Conditions
-----------------
Overactive Bladder

Intervention / Treatment
-----------------
* Drug: type A botulinum toxin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neurogenic urinary incontinence with urodynamic overactivity resistant to anticholinergic Exclusion Criteria: Pregnancy Bladder cancer Symptomatic urinary infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: type A botulinum toxin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complete urinary continence at baseline, and days 30, 90, 180, and 360 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of mictions or self catheterizations a day |  |  | 
| number of leakages, urgency adverse events |  |  | 
| guarding times |  |  | 
| urodynamics: bladder capacity, reflex volume, residual maximal capacity detrusor pressure, flow detrusor pressure |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
overactive neurogenic bladder
Pain Prevalence in the Trauma Population

Study Overview
=================
Brief Summary
-----------------
The incidence of pain in the post traumatic population is an area that has little to no investigation. This study seeks to determine the incidence and experience of pain in this vulnerable population at different time points - while in hospital, 4 weeks post injury, 3 months post injury.

Detailed Description
-----------------
This pilot study will be a convenience sample from trauma inpatients at the Sunnybrook Campus. The purpose of the study is twofold: to investigate the prevalence of chronic pain that develops in the trauma population at Sunnybrook, and to see if neuropathic pain exists in this population, acute and/or chronically.

Official Title
-----------------
Pain Prevalence in the Trauma Population at Sunnybrook Hospital

Conditions
-----------------
Trauma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Over 16 years of age ability to read / write in English ability to complete an informed consent Exclusion Criteria: history of chronic pain unable to give informed consent unable to read / write English

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of pain at 3 months post traumatic injury. |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
trauma, pain
Laparoscopy-assisted ERCP in Patients With Altered Gastric Anatome

Study Overview
=================
Brief Summary
-----------------
The purpose of this research study is to collect data on the technical aspects of Lasparoscopy-assisted ERCP and patient outcomes to help guide future medical care of patients with Roux-en-Y gastric bypass surgery.

Detailed Description
-----------------
Patients would have had a Roux-en-Y gastric bypass in the past that had altered their gastric anatomy. Now they have developed bilary and/or pancreatic problems that require and ERCP. With their altered gastric anatomy a standard ERCP would not be possible. Thus they are scheduled for a Laparoscopy-assisted ERCP.

Official Title
-----------------
Prospective Evaluation of the Clinical Utility of Laparoscopy-assisted ERCP in Patients With Altered Gastric Anatomy

Conditions
-----------------
Biliary Disease, Pancreas Disease

Intervention / Treatment
-----------------
* Procedure: Laparoscopy assisted ERCP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 years and older Altered gastric anatomy Scheduled to undergo laparoscopy-assisted ERCP Exclusion Criteria: Any contraindications to performing endoscopy Participation in another research protocol that could interfere or influence the outcomes measures of the present study. The subject is unable/unwilling to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Altered gastric anatomy<br>Patients who have an altered gastric who need an ERCP | Procedure: Laparoscopy assisted ERCP<br>* Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.<br>* Other names: Laparoscopy;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patients with altered gastric anatomy who need an ERCP |  | approximately one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
laparoscopy assisted ERCP, altered gastric anatomy
Avanz Phleum Pratense Maintenance Dose

Study Overview
=================
Brief Summary
-----------------
The purpose of the trial is to evaluate the efficacy of two dosing schedules of Avanz SQ+ (Standardised Quality) Phleum pratense compared to placebo in subjects with grass pollen induced allergic rhinoconjunctivitis with or without asthma.

Official Title
-----------------
Avanz Phleum Pratense Maintenance Dose

Conditions
-----------------
Allergic Rhinoconjunctivitis

Intervention / Treatment
-----------------
* Drug: Avanz Phleum pratense
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A history of grass pollen allergy Positive skin prick test to grass Positive Immunoglobulin E test to grass Exclusion Criteria: Other allergies overlapping the grass pollen season Severe Asthma (defined as a Forced expiratory volume in 1 second (FEV1) below 70 % after adequate treatment)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Avanz Phleum pratense 15,000 SQ+<br> | Drug: Avanz Phleum pratense<br>* Suspension for Injection, Every 6 weeks for one year<br>|
| Active Comparator: Avanz Phleum pratense 4,000 SQ+<br> | Drug: Avanz Phleum pratense<br>* Suspension for Injection, Every 6 weeks for one year<br>|
| Placebo Comparator: Injection with no active grass component<br> | Drug: Placebo<br>* Suspension for Injection, Every 6 weeks for one year<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recording of rhinoconjunctivitis symptoms |  | Daily recordings during the grass pollen season 2012 | 
| Recording of symptomatic allergy medication use |  | Daily recordings during the grass pollen seasons 2012 |